(Q37424366)

20 August 2017

1 reference

title

The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea (English)

1 reference

20 August 2017

0 references

0 references

Clostridium difficile

0 references

1 reference

Gareth C Parkes

1

1 reference

20 August 2017

Jeremy D Sanderson

series ordinal

2

1 reference

20 August 2017

Kevin Whelan

series ordinal

3

1 reference

20 August 2017

publication date

1 April 2009

1 reference

Lancet Infectious Diseases

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

237-244

1 reference

INTESTINAL FLORA IN NEW-BORN INFANTS

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clinical practice. Antibiotic-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

An in-vitro model of colonisation resistance to Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The influence of the normal flora on Clostridium difficile colonisation of the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Changing epidemiology of Clostridium difficile-associated disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

An epidemic, toxin gene-variant strain of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics--snake oil for the new millennium?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics, prebiotics or 'conbiotics'?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics for prevention of necrotizing enterocolitis in preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Effect of probiotic strains on interleukin 8 production by HT29/19A cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Functional modulation of enterocytes by gram-positive and gram-negative microorganisms

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Modulation of human dendritic cell phenotype and function by probiotic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Bacterial probiotic modulation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Interactions between Lactobacilli and antibiotic-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile — A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics for recurrent Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The effect of probiotics on Clostridium difficile diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics for treatment of Clostridium difficile-associated colitis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotic use in clinical practice: what are the risks?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Saccharomyces cerevisiae fungemia: an emerging infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Possible role of catheters in Saccharomyces boulardii fungemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Antibiotic susceptibility profiles of new probiotic Lactobacillus and Bifidobacterium strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970059-3

7 January 2021

10.1016/S1473-3099(09)70059-3

Identifiers

DOI

1 reference

20 August 2017

1 reference